ABSTRACT The fear of needles and pain prevents some patients from seeking intravitreal treatment, which drives our group to develop a needleless device for performing intravitreal injections. A prototype for an electro-magnetically actuated needleless injector, based on Halbach arrays, is described and characterized in a laboratory setting. The implication of the prototype for needleless ocular drug delivery is investigated. This investigation is intended to improve drug delivery of glaucoma medication with a safe needleless approach. We detail the design aspects of the injector and characterized the device with custom-made phantoms. It was observed that, despite delivering the drug bolus to the center, the viscous vitreous phantom indicated vorticities similar to counter rotating vortex pairs, which could cause damage to the retina. The observed peak velocity during the phantom experiments was 6.1 mm/sec at the retinal layer, indicating that the delivery bolus can impart shear forces to the retina via the vitreous.
I. INTRODUCTION
Intravitreal injections are used in treating ocular diseases, such as glaucoma, which develops from common diseases such as diabetes [1] , systemic hypertension [2] , or simply with aging [3] . Glaucoma (a chronic increase in intra-ocular pressure) increases the risk for vision loss where the damage is usually irreversible [4] . Glaucoma medication (Timolol, Betaxolol, Ecothiopate iodide, isoflurophate, Acetazolamide, Mannitol [5] ) are delivered via eye-drops, tablets and injections to control the disease progression. Our scope is specific to the treatment of ocular hypertension (typically above 21 mmHg but is patient dependent) via intravitreal drug delivery [6] . Traditional treatment utilizes a 31-guage needle inserted a few millimeters posterior to the corneal limbus. The actual insertion distance is patient specific, but is located at the pars plana (anterior to the ora serrata) and angled into the center of the eye. From the patient's perspective, the benefits of a needleless approach is primarily circumventing needle phobia [7] , additionally it could reduce pain and make the procedure easier to perform. Conventionally, local anesthetics (Amethocaine, Benoxinate and Proparacaine) are given to mitigate pain [5] . Further, there are reported benefits of a better drug dispersion profile [8] , [9] , which may improve drug delivery to the retina. However, the needleless approach should be demonstrated to not compromise safety over the conventional procedure. There exist a number of approaches for needleless drug delivery [10] , which differentiates in the methods for accelerating the drug (fluid or particle) to a high velocity [11] , [12] for penetration through a surface barrier. Generally, Bernoulli's principle is adopted and large volume of fluid is forced through a small orifice to achieve the high velocities; The small jet diameter and short injection time is the suggested ''evidence'' for reducing pain. Contrasting intra-ocular and transdermal [13] procedures, the injection emphasizes precision, avoiding possible damage to the retina [11] . It has been shown that electro-mechanical actuation can achieve a fine level of control [14] - [22] in real-time, which is useful for jet control after penetrating the sclera [23] ; The delivery-jet has to slow down sufficiently to prevent damage to the retina and delivers medication to the precise depth [17] - [22] . Electromagnetism has also been demonstrated for use in controlled drug delivery via the delivery of magnetic particles [24] - [26] . To further the research in magnetically actuated needle-free jet injectors, we propose a Halbach array inspired [27] - [29] actuator in this paper to investigate needleless intravitreal injections.
The primary contributions of the paper include, 1) The development of a novel actuator ( Fig.1 ), with high current stiffness and passive regulation owing to the Halbach design. Higher current stiffness allows high force for scleral penetration while the passive feedback regulation limits large forces towards the end of the injection phase; This prevents potential damages to the retina. 2) Development of phantom models to visualize the injection phenomenon with our needleless Halbach injector. The phantom model allows us to capture the injection dynamics via Particle Image Velocimetry (PIV) to examine the safety aspects of a needleless drug delivery. 3) This prototype and lab-based proof of concept, investigates the safety concerns of such an approach such that the benefits of needleless technologies can be applied to intravitreal drug deliveries. We observed that while the injection delivers the injectant jet to the center of the eye there can still be damage to the retina. This indicates that further work to understand and dampen the vorticities is prudent if such an approach is to be commercialized.
II. MATERIALS AND METHODS

A. NEEDLELESS HALBACH INJECTOR PASSIVE REGULATION
The passive regulation is a consequence of the alternating magnetic field direction and coil current direction. During the initial injection phase, large forces for sclera penetration is required (Fig.2a&b) ; when current is applied, the Lorentz interactions between the wire currents and the magnetic fields results in mechanical motion. This motion is dependent on the interaction surface area, which reduces over the injection stroke; parallel magnetic fields as circled in orange do not contribute to the axial motion directly. The specific lengths of each section can be tailored to meet specific patient needs. Towards the end of the injection phase, the coil passes the parallel magnetic field region, where the coil is simultaneously experiencing opposing fields giving rise to antagonistic forces (Fig.2c) . As the plunger displacement increases, the opposition forces increases thus dampening the motion. Adjustable fixation screws prematurely stop the plunger, allowing a reverse current to return the plunger back to the initial state. The implications of the passive feedback regulation changes the force constant over the injection stroke. The force constant of the injector (similar to a spring constant) represents the amount of force that the injector can produce for a given input current. The force constant is experimentally determined and the implication of such a model is exemplified via simulations. The force constant is fitted with a high order polynomial curve (Fig.3c) , representing the transition from the blue circle to the orange circle ( Fig.2b ) and dampening (Fig.2c) .
B. NEEDLELESS HALBACH INJECTOR SYSTEM
The block control diagram is shown (Fig.3a) . When electrical current is supplied, interactions between the magnetic field (generated by the arrangement of permanent magnets) and the current in the coils generate a magnetic force. The wire coils move due the Lorentz forces and transfers the acceleration to the plunger. Subsequently, displacements of the ampoule, ejects fluid at the nozzle. Our injector system follows a similar control diagram to [20] , converting an electrical signal to a mechanical output. In Indicates the actuator at the initial injection phase requiring high force for sclera penetration; when current is applied, the Lorentz interactions between the wire currents and the magnetic fields causes the mechanical motion. This motion is a function of the interaction surface area, which reduces over the injection stroke, as parallel magnetic fields as circled in orange do not contribute to the axial motion directly. The specific lengths of each section can be tailored to the injection phase needs. (c) Illustrates the final delivery phase into vitreous where the passive feedback kicks in to reduce forces. As the coil passes the parallel magnetic field region, the coil is simultaneously experiencing opposing fields giving rise to antagonistic forces. As the displacement of the plunger increases, the forces opposing the motion increases. Adjustable fixation screws prematurely stop the plunger, allowing a reverse current to return the plunger back to the initial state.
C. NEEDLELESS HALBACH INJECTOR FORCE CONSTANT
To characterize the force response of the Halbach actuator, we measured the impact force of the actuator at prescribed stroke-lengths (actuation stroke of 5 mm corresponds to a delivery dosage of about 50 µL) for a given unit-step input.
The experimental set-up is as shown (Fig.3b) . The results concur with predicted rapid decrease in the force-current response across the stroke (Fig.3c) . Two different voltage points were tested to confirm that results are a function of the actuator properties and not due to input voltage used. We tested at 12 V and 17.5 V, which corresponds to 1.1 A and 1.6 A steady state current. The current stiffness at different voltages are comparable (On average, there is 6.2% difference) suggesting that it is a property of the injector.
The maximum current stiffness value occurs at the start of the actuation and is 12.96 N · A −1 while the average is 6.91 N · A −1 . The third order polynomial fit has a Sum of Squared Residuals value of, R 2 = 0.9923.
D. NEEDLELESS HALBACH INJECTOR BULK MODULUS
The bulk modulus is a key parameter for the dynamics of the injection, especially for the initial high loading [22] , [30] .
Following the protocols outlined in [22] , we measured the combined bulk modulus of the ampoule at various injectant volumes (50 µL, 150 µL, 200 µL). Volumes less than 50 µL were not tested, as we were unable to accurately determine the volume in the ampoule. The orifice of the ampoule was sealed with epoxy to prevent fluid from leaving the ampoule. The force and displacements were recorded and converted to pressure and volumetric changes. The bulk modulus (B) is defined in equation (1) relating pressure to volume changes. Our results indicate the bulk modulus is a linear relationship as shown in (Fig.3e) ; we have excluded the preloading region in the model. Our combined bulk modulus follows the simple linear equation where the Sum of Squared Residuals value, R 2 = 0.993. The relationship between the bulk modulus and the ampoule volume is used in the ODE model.
E. NEEDLELESS HALBACH INJECTOR ODE
We modified existing ODE models [17] , [23] to represent our injector, equations (2), (3) & (4), where (P) is the pressure, (V) and (X) is the velocity and displacement of the plunger, the other symbols are defined in Table. 1. 
In addition, the equation for the input force F EM is given as the polynomial fit to (Fig.3c ) at an input current of 3A.
The set of ODE equations is solved in MATLAB based on an iterative Runge-Kutta-4 solver. Relative tolerance was set at 10 −5 and absolute tolerance set at 10 −6 , time step of 10 −4 sec and the total simulation time is 0.2 sec. We have modified the combined bulk modulus (B) to be a function of displacement as per Fig.3e . The model simulates the Pressure in the ampoule (P) and the Displacement of the plunger (x). (Fig.3d) is a pictorial representation for equations 2, 3 & 4 . As the plunger moves at a particular velocity, the fluid in the ampoule is compressed leading to an increase in pressure of the control volume. The increase in pressure is comprised of the displaced volume from the plunger and the compressed volume by the plunger. Pressure loss in the control volume is due to fluid volume escaping via the nozzle. From [30] , the Velocity of the fluid at the nozzle is rewritten in equation 2 as
The simulation results agree with the initial oscillatory patterns observed by [22] and [30] due to the reflection of the compression waves. Various polynomial orders to Fig.3c are tested and compared (Section III-A).
F. VITREOUS CHAMBER EXPERIMENTAL SET-UP
The set-up (Fig.4a) consists of the electromagnetic injector held in place by a retort stand with a clamp. The camera (GoPro Hero4) captures images at 30 fps, at a resolution of 1080p. Image frames are extracted using GoPro Studio and further processed in MATLAB. To visualize the flow, we seeded the vitreous with reflective particles (Fig.4e1) and used a dyed injectant (Fig.4e2) . The vitreous chamber is modeled as a cylinder instead of a sphere to allow a non-distorted view into the chamber. Dimensions of the orbit for simulations have been reported previously [14] , [31] , [32] , and we have opted to use a cylinder of 25 mm in diameter and 17 mm in length. This relates to an orbital 25 mm in diameter and a volume of around 8 mL. We are using an injection volume of 50 uL, which is a common injection volume. The vitreous is modeled with alginate dissolved in water and the concentration set such that the eventual viscosity of the solution is around 4000 cP [33] . This model is simple and does not capture the intricacies [34] of the vitreous but is sufficient for this initial phase of testing. The vitreous is housed in a silicon mould, which is in turn clamped between two clear 1.5 mm acrylic sheets. The model has a 10.9 mm by 17 mm rectangular opening where we can mount the phantom sclera and fill the vitreous cavity (Fig.4b) . The sclera barrier is simulated with Poly-CaproLactone (PCL) as suggested by [30] (Fig.4c&d) . Our sclera phantom is not as hard or tough as the actual sclera [29] - [34] , but was still able to serves as a penetration resistant membrane layer. We tested 0.8 mm PCL expanded with Calcium Carbonate, a 0.2 mm and 0.1 mm thick PCL-only barrier. Other membrane layers, (choroid and conjunctiva) are assumed negligible with respect to the sclera. The injector at higher voltages, above 50 V, penetrates biological tissue such as excised ) and (c) shows displacement and velocity respectively. The third order model is able to achieve higher initial pressures and decays at a faster rate, which benefits control to reducing the jet velocities at later stages of the injection. chicken skin. Due to safety limitations the subsequent experimental results were collected strictly under 30 V.
G. PARTICLE IMAGE VELOCIMETRY
We utilized the open source PIV toolbox, PIVlab [40] - [42] . The primary methodology used is direct cross correlation (DCC). The DCC method takes the peak in the correlation matrix (C(m, n)) as the most likely solution for the velocity (i, j) map at (m,n).
This method requires seeding particles (Fig.4e1) such that features from the previous frame can be contrasted with the current frame. The benefit of this method is the visualization of flow, while dye injectant can indicate the bulk position of drug. Ideally, the injection process should not disturb the vitreous situated near the retina. Prior to analysis, a contrast filter is used to enhance the detection with a RGB threshold filter.
III. RESULTS
A. ODE SIMULATION VARYING F EM POLYNOMIALS
The ODE simulation is explored by using the data points from (Fig.3c) ; the third, first and zero order polynomials are obtained by the least squared regression. The third order fit (which is the current model of the injector) represents the influence of the passive feedback dampening, exemplifying the case of a unit step impulse to our device (Fig.5 red line) . The physical interpretation of the first order model would be the case of a solenoid, but with a linearly decreasing current input (Fig.5 blue line) . The zero order model would be the case if the current was not decreased and the actuator had a constant force value (Fig.5 green line) . The passive feedback allows for both, a higher pressure generation at the start and a faster decay as indicated around the 0.06 second mark. Simulation results (Fig.5) , indicates that the higher order polynomial is able to achieve a higher injecting pressure and faster pressure decay rate.
B. INFLUENCE OF SCLERAL BARRIER
We tested 4 barrier conditions: no barrier, 0.1 mm barrier, 0.2 mm barrier and 0.8 mm barrier, (Fig.6) . The input voltage is 30 volts and there is a standardized 1 mm gap between the ampoule orifice and the membrane. Without a membrane, the injectant reaches the back of the phantom and as we increase the thickness (resistance) of the barrier; changes to the delivery depth is observed. Without resistance, the dispersion profile follows patterns similar to [13] and with resistance follows [38] . We further analyzed results from 0.1 mm membrane condition. The velocity magnitudes were greatest during the entry phase and peak observed was at 0.985 pix/frame = 3.8 mm/sec, (Fig.6b) . The conversion, 1 pix ≈ 0.13 mm, is based on an average of 187.3 pix ± 1.874pix corresponding to a 25 mm fiducial marker and each frame takes 1/30 sec. The velocity peak occurs when fluid reaches maximum vertical displacement, typically transitioning from frame 1/30 to 2/30. The time resolution of these results can be further improved with better equipment. The corresponding velocity magnitude at the retina for each time frame is shown (Fig.6c) . For frame 2 ( Fig.6c green line) the Maximum Velocity = 0.985 pix/frame (3.8 mm/sec) and Average Velocity = 0.47 pix/frame (1.8 mm/sec) with a standard deviation = 0.202 pix/frame (0.8 mm/sec). During the high velocity phase, the velocities near the medial and lateral retinal walls experience the greatest velocity magnitudes. The shears from the initial jet and the geometries are suspected to give rise to transient eddy currents where the energy is dissipated. From (Fig.6c) , it is suggested that the greatest velocity magnitudes occur along the retinal circumference and does not occur at the point of injection.
C. VARYING VOLTAGE
The effects of voltage variations on penetration depth are observed. To achieve drug delivery to the center of the eye, the voltage for the delivery phase is dependent on the viscosity of the injectant and the medium (vitreous). Tested voltages ranged between 14 V to 20 V; voltage outside this range leads to either a lack of actuation or excessive penetration depth. In general, an increase in voltage will increase the penetration depth and the dispersion of the fluid profile, (Fig.7a) . Comparing the 15 V and 16 V velocity magnitudes at the various frames utilizing PIV, (Fig.7b&c) ; it is observed that a small change in input can have significant difference (31.3% increase in of peak velocities) near the retinal layer. The peak of the 16 V input is 1.57 pix/frame (6.1 mm/sec), at 15 V it is 0.81 pix/frame (3.2 mm/sec). The average for 16 V is 0.57 pix/frame (2.2 mm/sec) and at 15 V is 0.43 pix/frame (1.7 mm/sec). The peak of 16 V occurs earlier than 15 V by about 2 frames (67 mSec).
D. JET FORCE MEASUREMENTS
A force torque sensor (ATI nano17) was used to measure the impact force of the jet in the vitreous phantom at various depths (35 The parameters of concern are the compressive force in the normal direction to the sensor surface (F z ) and the magnitude of the force vector (Mag,
. Comparison between the four depths did not have significant differences, contrary to our expectations. The 20 V input indicates higher F z than the 15 V. From the Mag plot it is observed that there are significant force components in the other directions possibly due to the increased eddy shears at low voltages.
IV. DISCUSSION
Through our prototype we observed that, even though the bulk volume of the drug is delivered to the center of the vitreous, there can be energy diffusion from the injectant to the vitreous, translating into a velocity component near the retinal layer. This is clinically relevant as the shear forces can aggravate retinal detachment, (Fig.8b&c) . To facilitate discussion, we adopt terminology from [15] to describe the injection delivery phases (after penetrating the sclera). (1) Reaching maximum injection depth, (2) injectant dispersion at maximum depth and (3) dispersion throughout the bolus volume. Additionally, phase (1) induces vorticities [44] shearing fluid posteriorly during phases (2&3), (Fig.8A) . This affects the final bolus profile of the injectant in the vitreous. The effects of injection voltage contribute to the velocities observed in (Fig.7) and are likely due to the fluidic eddies [45] . A small change in the voltage (15 V, 16 V) affects the penetration depth of the injectant and the profile of the injectant. Increasing the voltage delays the onset of phase (3) . From force measurements at (15 V & 20 V) , the phases in concern are different. At 20 V, phase (1) delivers the greatest force while at lower voltages, which are more applicable to drug delivery, the forces are delayed and spread out over various component directions. This indicates that shear forces should be looked into with greater concern. Analysis into the PIV slices support the notion where the greatest velocity magnitudes do not occur at point of injection but rather surrounding it, (Fig.6c) . If we assume retinal attachment pressure to be 476 Pa [14] and a contact area of 10 mm disc, the sustainable force is 0.0374 N. From the test in Section III-D at 15 V the peak force was below 0.02 N, indicating that there is still a possibility of device implementation. Scleral thickness plays a significant role in the penetration mechanics. Given the huge variability in patient sclera for both thickness and failure thresholds, it appears unlikely that a simple feedback controller can accurately determine the injection depth after penetrating the sclera layer. To address this challenge, the resistance of the sclera must be further accounted for in the model or further tracking of the injectant bolus will be necessary to control the penetration depth.
V. CONCLUSION
We have designed a Halbach array based magnetic actuator for needleless intravitreal injections. The Halbach design has passive feedback, which reduces the force constant over the injection stroke (Fig.2&3c) , which helps to decelerate the injectant and prevent retina damage. The injector has a high current stiffness (12. 96 N · A −1 ) at the start of the injection stroke, which is necessary for injectant acceleration to penetrate the sclera. We fabricated an injection phantom, which allowed visualization of the injection dynamics (Fig.4) to better understand the delivery event.
The results are processed with PIV to analyze the velocity fields during injection where we experimented with three variables relevant to needleless intravitreal drug delivery (Fig.6&7, Section III-D) . We observed that the effects of scleral thickness as a penetration barrier cannot be ignored as it does affect penetration depth. Shearing forces and velocities proximal to the maximum injection depth should be further analyzed for future clinical applications of the device.
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